Supplementary Table 2. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
收藏数据链接：
官方服务：
资源简介：
<b>Supplementary Table 2</b>. Real world data on treatment outcomes in EGFR mutant NSCLC patients receiving osimertinib in second or further lines Cox regression univariate and multivariate analysis including all covariates potentially impacting on progression free survival.
提供机构：
Taylor & Francis创建时间：
2021-05-14
